• Novavax’s COVID Vaccine Candidate Left off White House List; 5-Star Analyst Explains the Implications

    Novavax’s COVID Vaccine Candidate Left off White House List; 5-Star Analyst Explains the ImplicationsThe Trump administration picked out five companies it believes are most likely to produce 2020’s holy grail – a vaccine for the coronavirus. Unfortunately, Novavax (NVAX) was not on the list.Although the White House didn’t disclose what lay behind the choices, 5-star B.Riley FBR analyst Mayank Mamtani provided some possible explanations.3 of the choices already have clinical studies in various degrees of progress (Moderna, AstraZeneca/Oxford University and Pfizer/BioNTech), whilst Novavax only began enrollment late last month. This implies to Mamtani that “speed to market entry” could be a major factor in the decision-making process.Whilst “risk diversification and cost sharing,” and a preference for large companies (Johnson & Johnson, Merck) with the necessary balance sheet required to conduct the extensive and pricey vaccine development and manufacturing may also be contributing factors.Even so, while those reasonings might explain the smaller player’s omission, Mamtani maintains Novavax should be added to the list.Mamtani said, “We remain encouraged by the de-risked nature of NVAX's vaccine candidate, on the basis of the most extensive preclinical data generated to date, and now reviewed closely by the global scientific community residing with CEPI, WHO, and SII, as well as U.S. agencies such as CDC, NIH-NIAID, and BARDA. We believe adding NVAX's NVX-CoV2373 on the basis of its proprietary adjuvanted recombinant nanoparticle platform could further help diversify development risk as well as tap into a relatively clearer path to market and manufacturing scale-up that NVAX has made tangible progress on recently…”To this end, Mamtani reiterated a Buy on NVAX and has a $74 price target, indicating the potential for 60% upside over the next year. (To watch Mamtani’s track record, click here)All other 4 analysts to post a Novavax review over the last 3 months recommend the stock a Buy, too. A Strong Buy consensus rating is accompanied by a $49.20 price target, implying room for an 11% uptick in the months ahead. (See Novavax stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/2Xzkip8

  • These were the worst performers on the ASX 200 last week

    man looking down falling line chart, falling share price

    It certainly was a fantastic five days for the S&P/ASX 200 Index (ASX: XJO) last week. The benchmark index stormed 4.2% higher over the period to end at 5998.69 points.

    Not all shares were able to climb higher with the market, though. Here’s why these were the worst performers on the ASX 200:

    The Gold Road Resources Ltd (ASX: GOR) share price was the worst performer on the ASX 200 last week with a 14.4% decline. This was driven by a pullback in the gold price after risk appetite improved. A number of other gold miners including Evolution Mining Ltd (ASX: EVN), Northern Star Resources Ltd (ASX: NST), Saracen Mineral Holdings Limited (ASX: SAR), and Silver Lake Resources Limited (ASX: SLR) were also among the worst performers during the week.

    The Nufarm Limited (ASX: NUF) share price was a poor performer last week and fell 8.9%. This decline appears to have been driven by a broker note out of Macquarie. According to the note, the broker downgraded Nufarm’s shares to an underperform rating with a $4.85 price target. Its analysts were underwhelmed with its trading update and appear concerned over its prospects in the important fourth quarter.

    The Pro Medicus Limited (ASX: PME) share price was out of form and fell 8% over the period. This was despite the healthcare technology company announcing a major contract win. It appears as though a broker note out of UBS offset this good news. The broker downgraded Pro Medicus’ shares to a neutral rating with a $29.65 price target. It made the move on valuation grounds.

    The TPG Telecom Ltd (ASX: TPM) share price wasn’t far behind with a 7.2% decline last week. It looks as though some investors were taking a bit of profit off the table after a strong share price gain over the last month. TPG Telecom’s gain since the beginning of May was driven by optimism over the progress it is making with its merger plans with Vodafone Australia.    

    Need a lift after these declines? Then you won’t want to miss out on the five recommendations below…

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post These were the worst performers on the ASX 200 last week appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2UeTMzj

  • Building a $100,000 portfolio with Afterpay shares and 3 other ASX companies

    asx growth shares

    Building long-term wealth through an ASX growth portfolio and inclusions like Afterpay Ltd (ASX: APT) shares is a lucrative path tempting many investors. Sure, you don’t get the certainty and income that more mature, dividend-paying companies can offer. But hitching your wagon to a real winner can be a life-changing experience.

    So, with that in mind, here’s how I would build a $100,000 ASX portfolio with ASX growth shares.

    Spend $25,000 on Xero Limited (ASX: XRO) shares

    Xero has been one of the biggest growth stars of the ASX for a few years now – and for good reason. This cloud-based software as a service (SaaS) company has baked up a storm with stellar subscriber growth numbers and a scalable business model. Last year alone, this company grew its subscribers by double digits in the target markets of the United Kingdom, the United States and Australia.

    It grew revenue by 30% – giving an indication of the company’s potential. Perhaps, unfortunately, the market has long known about its potential and shares are, therefore, priced accordingly. But that doesn’t stop a real winner in the end.

    Spend $25,000 on BetaShares Global Cybersecurity ETF (ASX: HACK) shares

    Aside from having my favourite ticker symbol on the ASX, I think this exchange-traded fund is a worthy investment for a growth portfolio. As the name implies, this ETF invests in companies operating in the digital security sector.

    I think the demand for cybersecurity services will continue to rise with the flood of commerce moving online every year (clearly accelerated in 2020). And these are exactly the kinds of companies HACK invests in. Some of its current holdings include Crowdstrike, Splunk, Cisco, and Palo Alto.

    Spend $25,000 on Pushpay Holdings Ltd (ASX: PPH) shares 

    Pushpay is another payments company. But unlike Afterpay’s buy now, pay later offering, this business targets the very niche area of donation management. It provides a model for any organisation that might still rely on the old ‘pass the hat around’ funding model – think churches and charities.

    The signs of the trend toward a cashless society are now becoming incontrovertible. This stems heavily from the coronavirus pandemic. As such, I think this company is worth having some faith in.

    Lastly, spend $25,000 on Afterpay shares 

    Finally, you can’t have a real ASX growth portfolio without at least considering this wunderkind. And after consideration, I think Afterpay shares more than deserves a role in our growth portfolio. This company has a remarkable track record of proving its detractors wrong over its short life. It has been able to easily crack the US and UK markets and appears to be growing strongly throughout this recent coronavirus crisis, despite fears over credit risk.

    I think Afterpay has a decent chance at one day rivalling the US-listed payment giants like Mastercard (NYSE: MA), Visa (NYSE: V) and American Express (NYSE: AXP). Thus, I think it’s a deserving company to have in our ASX growth shares portfolio.

    For some more shares you might want to add to your list, don’t miss the free report below!

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of AFTERPAY T FPO, PUSHPAY FPO NZX, and Xero. The Motley Fool Australia owns shares of BETA CYBER ETF UNITS. The Motley Fool Australia has recommended PUSHPAY FPO NZX. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Building a $100,000 portfolio with Afterpay shares and 3 other ASX companies appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/379bfhY

  • Edited Transcript of ONTX earnings conference call or presentation 14-May-20 8:30pm GMT

  • Uber cuts 3,000 more jobs, shuts 45 offices over coronavirus pandemic: WSJ

  • Despite PPP aid, some small businesses are choosing to stay closed – here’s why

  • Stock market news live updates: Moderna coronavirus vaccine fuels rally; Uber braces for new layoffs